2017

06_Pieris
December 7, 2017
Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program

 

lophius
October 12, 2017
Biomax Informatics’ NeuroXM™ Suite Wins Innovation Award

 

lophius
September 01, 2017
Launch of the Next Generation T-Track® CMV Immune Monitoring Tool

 

05_Paratek
July 17, 2017
Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections

 

06_Pieris
June 27, 2017
Pieris Pharmaceuticals Added to the Russell 2000(R) and Russell 3000(R)
Indexes

 

amicra
June 23, 2017
AMICRA Announces New Headquarter Building

 

OneAccess Networks IP broadcast solutions for wireless networks France
June 08, 2017
OneAccess Networks enables Telia Company to Launch World's First Commercial 4G Mobile Access for Carrier Ethernet Services

 

06_Pieris
June 04, 2017
Pieris Pharmaceuticals Announces Presentation of Clinical Data for Anemia Drug Candidate, PRS-080

 

05_Paratek
June 03, 2017
New Microbiology Data Reinforce Activity of Paratek's Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections

 

03_Memo
May 23, 2017
Memo Therapeutics AG announces proof of concept of its huMemoMABTM antibody technology platform

 

06_Pieris
May 15, 2017
Isarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma

 

06_Pieris
May 03, 2017
Pieris Pharmaceuticals and AstraZeneca Collaborate

 

lophius
April 05, 2017
Clinical Validation of T-Track CMV, a Highly Sensitive Immune-Monitoring Tool

 

06_Pieris
April 04, 2017
Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate

 

05_Paratek
April 03, 2017
Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia

 

01_EnOcean
March 27, 2017
Allergan and Paratek Announce Positive Results From Two Phase 3 Trials

 

06_Pieris
March 22, 2017
Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update

 

lophius
March 16, 2017
Lophius Biosciences Completes Extension of its Financing Round to €7.36 Million

 

06_Pieris

February 27, 2017
Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutica

 

05_Paratek
January 18, 2017
Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study

 

01_EnOcean
January 17, 2017
Andreas Schneider Becomes the New CEO of EnOcean

 

06_Pieris
January 5, 2017
Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance